Join to View Full Profile
161 Fort Washington AveNew York, NY 10032
Phone+1 212-305-5098
Dr. Sawas is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ahmed Sawas is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 11 years. He specializes in hematologic oncology and is experienced in cutaneous t-cell lymphoma of the penis, cold agglutinin disease, cold autoimmune hemolytic anemia, and oropharyngeal lymphoma. He has more than 30 publications and over 500 citings.
Education & Training
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012- Westchester Medical CenterResidency, Internal Medicine, 2006 - 2009
State University of New York Downstate Medical Center College of MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2009 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2014-2017
Clinical Trials
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Start of enrollment: 2013 Mar 01
- Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
- Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) Start of enrollment: 2014 Mar 05
Publications & Presentations
PubMed
- Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens.Jennifer Prescott, Christina M Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang
Blood Neoplasia. 2026-08-01 - Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.Hua-Jay J Cherng, David DeStephano, Patrick Gould, David Sabatino, Alexander D Sanjurjo
Leukemia & Lymphoma. 2026-06-07 - Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.Colin J Thomas, Min Jung Koh, Omar Elghawy, Jessy Xinyi Han, Leora Boussi
Leukemia & Lymphoma. 2026-05-01
Journal Articles
- Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin LymphomaChangchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology
Press Mentions
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-Positive LymphomaDecember 7th, 2020
Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell LymphomaNovember 9th, 2019
Affimed Reports Financial Results for Third Quarter 2018 and Operational ProgressNovember 7th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
